Sutro Biopharma (NASDAQ:STRO – Free Report) had its price target cut by HC Wainwright from $16.00 to $12.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Sutro Biopharma’s Q1 2024 earnings at ($0.95) EPS, Q2 2024 earnings […]